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Abstract
Background Cervical intraepithelial neoplasia (CIN), a
frequently encountered disease caused by Human Papilloma
Virus (HPV) is often diagnosed in formaldehyde-fixed
paraffin embedded (FFPE) punch biopsies. Since it is known
that this procedure strongly affects the water-soluble proteins
contained in the cervical tissue we decided to investigate
whether a water-soluble protein-saving biopsy processing
method can be used to support the diagnosis of normal and
CIN.
Methods Cervical punch biopsies from 55 women were
incubated for 24 h at 4°C in RPMI1640 medium for protein
analysis prior to usual FFPE processing and p16 and Ki67-
supported histologic consensus diagnosis was assessed. The
biopsy supernatants were subjected to surface-enhanced
laser desorption-ionization time of flight mass spectrometry
(SELDI-TOF MS) for identifying differentially expressed
proteins. Binary logistic regression and classification and
regression trees (CART) were used to develop a classifica-
tion model.
Results The age of the patients ranged from 26 to 40 years
(median 29.7). The consensus diagnoses were normal
cervical tissue (n=10) and CIN2-3 (n=45). The mean
protein concentration was 1.00 and 1.09 mg/ml in the
normal and CIN2-3 group, respectively. The peak detection
and clustering process resulted in 40 protein peaks. Many
of these peaks differed between the two groups, but only
three had independent discriminating power. The overall
classification results were 88%.
Conclusions Water-soluble proteins sampled from punch
biopsies are promising to assist the diagnosis of normal and
CIN2-3.
Keywords Cervical intraepithelial neoplasia . CIN .
Proteomics . SELDI-TOF.Mass spectrometry
1 Background
Among the cancers affecting women, cervical cancer has
the second highest occurrence worldwide. In developing
countries where 80% of the deaths caused by this disease
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occur, it is the cancer type that affects most women [1]. The
most important risk factor associated with the development
of cervical cancer is the infection of cervical epithelial cells
by high-risk Human Papilloma Virus genotype (hr-HPV)
[2]. The tumor development can take 10–25 years, during
this time the cervical epithelium develops a non-invasive
neoplastic lesion called cervical intraepithelial neoplasia
(CIN) [3]. The World Health Organization distinguishes
three CIN grades (CIN1, CIN2 and CIN3) according to the
degree of epithelial abnormality. This can easily give the
faulty impression of a solidified sculpture, as if the three
CIN grades are static events, whereas in reality a CIN
lesion is a dynamic process that can persist and progress but
also regress [4]. When CIN2-3 is diagnosed in a histolog-
ical punch biopsy, definitive therapy by cone excision is
usually promptly performed [5]. The reason for this
aggressive invasive therapy is that 5–30% of CIN2-3
patients will eventually develop invasive cancer when left
untreated. However, at the same time many (10–40%)
CIN2-3 s will regress spontaneously [6]. Recently, it has
been shown that functional biomarkers such as Ki67, pRb,
p53 and cytokeratine 13/14 are helpful in the prediction of
regression or not, and the aggregate information provided by
these biomarkers exceeds the value of the classic grading
system. Consequently, many more CIN-lesions that can either
regress or progress could be more accurately treated [7].
Although these methods are very promising, the fixation
process of fresh tissues, required for conventional micro-
scopical and many immunohistochemical stains leads to
loss of water-soluble proteins that could be of interest. In
addition it affects the remaining proteins by introducing
different crosslinks that can make it difficult to obtain them
for identification after the fixation process [8–11]. Some of
the protein modifications introduced by the fixation process
may also lead to misidentifications [9]. Cytokines and
chemokines are examples of such proteins whose charac-
terization in CIN-lesions could give valuable information
about the patient’s immune reaction against the HPV-
infection [12–14].
As the HPV-infection induces a local immune response
in the cervix that is barely detectable at plasma/serum level
[15] it is important to establish a standardized method for
collection of a sample that truly represents the cervix
microenvironment. In order to achieve this, several studies
have been performed using different sample types like
cervicovaginal washings [14, 16], cervical mucus [17] and
cells supernatant from cytobrush collection [18], employing
different analysis technologies. One of these technologies is
surface-enhanced laser desorption-ionization time of flight
mass spectrometry (SELDI-TOF MS) which is a powerful
tool for identifying differentially expressed proteins. These
proteins can be potentially diagnostic and prognostic
biomarkers in neoplasia [19, 20].
The aim of this study was to develop a protein-saving
biopsy processing method with similarities to the method
published by Celis et al. [21], and to utilize SELDI-TOF
MS to analyze the proteins from the biopsies, while at the
same time preserving the tissue for conventional micro-
scopic and immunohistochemical studies. In this pilot
study, we will investigate if it is possible to separate normal
cervical tissue from CIN2-3 lesions.
2 Methods
2.1 Study population
The current study is a sub-project from a larger prospective
study, approved by the RegionalMedical Ethics Committee of
Helse Vest, Norway, the Norwegian Data Inspection, and the
Health Directorate of Norway, #33.06, #17185 and #07/330.
Two hundred and fifty-six patients have been enrolled in this
prospective study. The criterion for selection in this large
prospective study is a cytological abnormal smear followed
by cervical biopsy in women with previously normal smears.
Of these 256 patients with cervical punch biopsy samples, 45
diagnosed as CIN2-3 (n=45) were selected. From women in
the same age range, biopsies that were histologically and
immunohistochemically normal (n=10) were also used.
2.2 Sample collection
For soluble protein recovery, biopsies of normal and
cervical neoplastic epithelium were collected and immedi-
ately placed in polystyrene tubes (Sarsted, Nurmbrecht,
Germany) containing 5 ml of RPMI1640 culture medium
(Gibco, Carslbad, USA) and stored for 24 h at 4°C.
Afterwards, the supernatants were collected, split into
aliquots of 500 μl and stored at −80°C until analysis.
2.3 Pathology
After 24 h incubation in the RPMI1640 medium, the
biopsies were routinely fixed in buffered 4% formaldehyde,
embedded in paraffin, cut at 4 μm, and stained with
hematoxylin, eosin and safran (HES) for routine micro-
scopic examination. P16 and MIB-1 immunostainings were
used to confirm the diagnosis and Human Papilloma Virus
genotype determinations were done in all cases. All
biopsies were reviewed by two pathologists, who were
blinded to the original diagnosis and follow-up; in case of
discrepancies the cases were re-reviewed with a double-
head microscope by two pathologists (EG, JB) who also
used the immunohistochemical stains and a consensus
diagnosis was always obtained. The cases were diagnosed
as follows: normal (n=10) and CIN2-3 (n=45).
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2.4 Immunohistochemistry
The protocol for immunohistochemistry, type/manufacturer
and dilution of the antibodies p16 and Ki67 has been
described before [7]. For the epithelial biomarkers the
following antibodies and dilutions were used: CK-13 (clone
KS-1A3, Novocastra, Newcastle upon Tyne, UK) 1/200;
CK-14 (clone LL002, Novocastra, Newcastle upon Tyne,
UK) 1/40; pRB (clone 13A10, Novocastra, Newcastle upon
Tyne, UK) 1/25; p53 (clone DO-7, DAKO, Glostrup,
Denmark, S3002) 1/200; PhosphoHistone=PPH3 (Polyclonal
Cell signaling solutions, Upstate #06-570; Lake Placid, NY,
Fig. 1 Typical examples of
cervical biopsies after 0
and 24 h incubation in RPMI.
Note that there are no visible
differences after 24 h incubation
Discriminating CIN from normal tissue by protein profiles 445
USA) 1/1500. The section adjacent to the sections used for
immunostainings was cut and stained with H&E to ensure the
presence of the same CIN lesion in all test sections
(“sandwich-technique”).
2.5 ProteinChip SELDI-TOF MS analysis
Protein concentrations were assessed using a spectrophotom-
eter (Thermo Scientific NanoDrop Spectrophotometer) mea-
suring the absorbance at 280 nm. An equal amount of total
protein (10 μg) was used. Samples were subjected to SELDI-
TOF MS profiling according to the manufacturer’s instruc-
tions (Ciphergen Biosystems, Fremont, CA, USA). The
biopsy supernatants were diluted 1:5 with 50 mM sodium
acetate (pH 4.3) and then bound to a CM10 ProteinChip array.
They were incubated for two hours at room temperature on a
platform shaker, then washed twice with 50 mM sodium
acetate buffer, followed by two times 1 μl of energy absorbing
molecule (=EAM) solution (consisting of 50% saturated
synaptic acid dissolved in 50% acetonitrile and 0.5%
trifluoroacetic acid). Two replicates were prepared on differ-
ent CM10 ProteinChips by two different analysts on two
different days. The time-of-flight spectra were generated on
the Protein Biological System II mass spectrometer reader
(Ciphergen Biosystems, Fremont, CA, USA), using a laser
intensity of 170, and a detector sensitivity of seven. Readings
were optimized for low molecular weight (2–20 kDa).
External mass calibration was performed daily.
2.6 Data analysis
The SELDI-TOF MS data analysis was performed in three
steps: 1) peak detection, 2) selection of peaks with the
highest discriminatory power and 3) building a multivariate
model based on the selection in step 2. The peak detection
was done using the Ciphergen Seldi software version 3.2
after internal and external mass calibration followed by
normalization (TIC intensity) of all spectra as one group.
The mass range from 2000 to 20000 Da contained the
majority of the peptides/proteins in the samples, and was
selected. Masses less than 2000 Da was excluded as these
are known to contain adducts and artifacts from the EAM-
solution and other chemical contaminants. The peak
detection includes baseline subtraction, calibration of mass
accuracy and automatic peak detection. Each spectrum was
then assigned to one of two groups, normal or CIN2-3. To
select peaks with the highest discriminatory power, the
Biomarker Wizard (Ciphergen) was used for peak detection
and clustering of all the spectra. This was done using a
signal-to-noise (s/n) ratio of 5 and 15% of all spectra for the
first pass detection and clustering, and an s/n ratio of 2 for
the second pass. The cluster results were then imported into
SPSS version 15 (SPSS Norway AS, Oslo, Norway),
CART (Salford, San Diego, CA, USA) and MedCalc
(MedCalc Software, Mariakerke, Belgium) for binary
logistic regression analysis and Classification and Regres-
sion Tree analysis. A t-test was done, a correlation test
using all 40 peaks followed by the development of a binary
logistic regression model using the peaks that were found
not to be correlated.
3 Results
The median age of the patients at the time that the biopsies
were obtained was 30.8 years (range 26–40) for the CIN2-3
Fig. 2 Zoom views of SELDI-
TOF MS spectra show
different expressions in protein
profiles between normal
(three bottom graphs) and
CIN2-3 (three top graphs)
for the three peaks
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group and for the normal biopsies group, 33.1 years (range
32–34) (these differences were not significant). The mean
protein concentrations of the normal (1.00 mg/ml) and the
CIN2-3 (1.09 mg/ml) samples were also not significantly
different. We did evaluate the effect of different incubation
times on the histology and immunohistochemistry on
cervical biopsies. Figure 1 gives typical examples, showing
that after 24 h incubation, there are no visible differences
compared with 0 h incubation.
The peak detection and clustering process using Bio-
marker Wizard resulted in a total of 40 protein peaks. The
development of a binary logistic model resulted in three
peaks found to have independent value in discriminating
the two groups. Figures 2 and 3 show zoom views of the
differential peaks and examples of full spectra (m/z 2000–
10000) for the 2 groups analyzed. As Fig. 2 shows, the
peak with m/z 3430 is down-regulated in CIN2-3 samples
compared to normal samples, while the peaks with m/z
5077 and 7794 up-regulated. The reproducibility between
the technical replicates and between samples can be seen in
Fig. 3 where the replicates for three different CIN2-3
samples are visualized as gel traces (gel view).
The reproducibility of the analysis was tested by
comparing all 40 peaks between replicate 1 and 2. Only
three of the 40 peaks were significant different between
replicate 1 and replicate 2, i.e. m/z 3318 (p=0.01), m/z
4023(p=0.0001) and m/z 10885 (p=0.03). All other peaks
had p values higher than 0.10 and the three discriminatory
peaks were not different at all (P>0.80). When the
multivariate analyses were repeated leaving out the peaks
that were significantly different between the two replicates,
the discriminatory results between the normal and CIN2-3
samples were the same as before.
Table 1 summarizes the 3 discriminant peaks. The
average intensities, confidence intervals and the probabili-
ties of no difference (t-test) between the normal and CIN2-3
groups assuming independency are shown. Figures 4, 5 and
6 shows the discrimination of the two groups using the
three SELDI-TOF MS peaks as variables. By using the
developed three-step binary logistic model, an overall
correct classification of 88% was obtained. 14 of the 20
normal samples and 84 of 90 of the CIN2-3 samples were
correctly classified.
4 Discussion
This study presents the results obtained from analyzing
protein extracts obtained by a novel method by SELDI-
TOF MS. We have shown that water-soluble proteins
sampled from punch biopsies are promising to assist the
diagnosis of normal and CIN2-3.
We found that 24 h immersion of cervical punch biopsies
in RPMI at 4°C can be used to harvest 1 mg/ml water
soluble proteins without compromising the routine immu-
nohistochemical analysis of the tissue. Moreover, the water
soluble proteins from the biopsies give good discrimination
between samples with normal and CIN2-3 epithelia.
SELDI-TOF MS technology has been applied for several
years to address the need for new markers for early cancer
detection [19, 22–24] or for different lymphomas [25].
Most studies have compared diseased and healthy persons
Fig. 3 One normal trace for sample 1 combined with gel traces (gel
view) showing the protein profiles for both replicates of three
representative CIN2-3 samples (labelled 1–3) covering the m/z range
from 2000 to 10000
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Table 1 Mean intensities and confidence intervals (in parenthesis) for proteins differentially expressed between normal cervical tissue and CIN2-
3 samples. The probability of no differences (t-test) between normal and CIN2-3 samples is presented as p-values
Protein m/z Normal (n=10) CIN2-3 (n=45) p-value (Normal vs CIN2-3)
Mean intensity Mean Intensity
3430 19.0 (13.54–24.52) 7.3 (6.43–8.16) <0.0001
5077 10.7 (5.67–15.82) 26.9 (22.74–31.07) 0.0006
7794 1.7 (1.15–2.24) 7.3 (6.22–8.44) <0.0001
and have been useful for a better understanding of the
development of several types of cancer. However, it is more
difficult to develop biomarkers which can discriminate
between the different development stages of a neoplasia as
the differences are much smaller than between healthy and
diseased persons. Yet, the model presented here shows that
this still is possible with the technology used. CIN
represents the first step in the development of cervical
cancer through the three different CIN phases. In a future
study, it is important to analyze whether SELDI-TOF MS
or other mass spectrometric techniques can discriminate
between CINs that will regress spontaneously from CINs
that will persist or progress to invasive cancer. Furthermore,
the protein collection method that was developed is of great
interest for studying not only cervical neoplasia but it could
also be applied to other organ tracts. The method of placing
a biopsy in a cell culture medium for 24 h at 4°C is
considerably longer than 1 h in PBS at 37°C used by Celis
et al. [21], and enables the collection of proteins from a
biopsy without interfering with the essential diagnostic
information. The three peaks found to separate normal
tissue and CIN2-3 lesions did not have the same m/z-values
as those reported found from SELDI-TOF MS analysis of
cell lysates of normal and invasive cervical cancer [26] or
from plasma samples of CIN patients [27]. The protein
concentrations in the samples were comparable to those
found in samples frommucosal collection using sponges [28].
In addition, the RPMI immersion method has additional
value to conventional FFPE analysis as it enables the
collection and analysis of water soluble proteins which are
not available from formalin-fixed paraffin-embedded tissue
protein extracts. Proteins like cytokines and chemokines are
collected in a volume enabling the analysis by different
techniques like SELDI-TOF MS, LC-MS/MS or by ultra-
sensitive Elisa techniques like electrochemiluminescence.
The reviews published by Dijkstra et al. [29] and
DeBock et al. [30] discuss several sources of variation that
needs to be addressed. An essential aspect of a new
laboratory test with possible diagnostic and therapeutic
implications is the variation sources in all steps of the
analysis [31]. These include: 1. Pre-analytical (a. each time
getting the same samples, by using the same biopsy device;
b. taking two samples from the same patient and put them
Fig. 5 Scatterplot showing the discrimination of the two groups using
m/z 5077 and 7794 as variables. Blue circles: Normal samples. Red
triangles: CIN2-3 samples
Fig. 4 Scatterplot showing the discrimination of the two groups using
m/z 3430 and 7794 as variables. Blue circles: Normal samples. Red
triangles: CIN2-3 samples
Fig. 6 A three-dimensional scatterplot showing the discrimination of
the two groups using all three peaks. Blue circles: Normal samples.
Red triangles: CIN2-3 samples
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in two different RPMI tubes; c. standardize the incubation
conditions and time); 2. Analytical part (a. binding and
cleanup on the SELDI-chip; b. reproducibility of the
SELDI-TOF measurement of the same sample; c. take two
samples from the same RPMI sample and test the
reproducibility); 3. Post-analytical (a. peak processing and
clustering; b. data analysis).
As to sampling device, we always used the same
biopsy forceps. The samples were all taken by the same
experienced gynaecologist. We also analyzed two nearby
samples from 5 consecutive patients and compared the
results. Two neighbouring biopsy samples in the cervix
from the same patient also gave comparable results. We
standardized the incubation conditions (RPMI, 4oC) and
time (24 h).
As to the analytical part, all the technical aspects of the
Seldi chip were standardized as described. We also tested
the reproducibility of the same samples (see Fig. 3).
Moreover, two different technicians analyzed the same
samples, with the same results.
As to peak processing, clustering and data analysis, we
used strictly protocolized standard operation procedures.
The results are promising but should be confirmed in a
larger set of independent samples. In an ongoing study not
published yet, a subset of supernatants has been character-
ized using LC-MS/MS. Further work to identify the
candidate biomarkers found using this model will be done
using LC-MS/MS (one- or multidimensional [32, 33]) of
tryptic digests after fractionation by chromatography or
two-dimensional gel electrophoresis [34]. An identification
of the possible biomarker candidates found using this
model will possibly give new insight to the mechanisms
related to the Human Papilloma Virus infection.
5 Conclusions
Immersion of cervical punch biopsies for 24 h in RPMI
tissue culture medium allows the analysis of water
soluble proteins that can assist in the diagnosis of
cervical intraepithelial neoplasia without interfering with
the diagnosis. We conclude that the water soluble
proteins from the biopsies provide good discrimination
between normal and CIN2-3 samples. This is a promising
strategy to study the dynamic behavior of CINs and
hopefully will allow identification of regressive and non-
regressive CIN2-3 lesions and a better indication of
patient-tailored treatment.
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